Beijing GoBroad Hospital uses advanced cellular manufacturing techniques and immunotherapy protocols to provide CAR T-cell therapy services. Founded in 2017, this institution is based in Beijing, China, and it has adequate bed capacity, with recognition, to assist both local and foreign patients.

The CAR-T process is beneficial for some patients with blood cancers that have failed prior treatment and returned, depending on the disease type and the approved indication. In CAR-T therapy, T cells are collected, engineered to recognise cancer cells, multiplied, and then infused back after proper preparation of the cells. The cancer treatment team performs a careful assessment of the disease and health history before individualisation of treatment.